TAYSHA GENE THERAPIES INC
TSHANASDAQ🏆 #1804 by market capEarnings Nov 10US Equity
$6.29▼ $0.37 (−5.91%)
Live1h▼ 1.2%
24h▼ 5.9%
7d▼ 2.9%
14d▲ 11.8%
30d▲ 16.8%
1y▲ 116.7%
🏦Market Cap
$2.01B
Small Cap
📈Revenue Growth (YoY)
+3.4%
Slowing
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
208.5x
Expensive
Otter Score
48
Weak
📊
Analyst Ratings
Price
$6.29
Total
18
Raised
0
Lowered
2
Avg PT
$14.00
H / L
$15 / $13
| Institution | Action | Rating | Date |
|---|---|---|---|
Goldman Sachs | Reiterated | Buy | 2026-07-21 |
Citizens | Reiterated | Market Outperform | 2026-07-02 |
Baird | Reiterated | Outperform | 2026-06-30 |
Needham | Reiterated | Buy | 2026-06-30 |
B of A Securities | Reiterated | Buy | 2026-06-23 |
BMO Capital | Reiterated | Outperform | 2026-06-23 |
Canaccord Genuity | Reiterated | Buy | 2026-04-06 |
Chardan Capital | Reiterated | Buy | 2026-03-19 |
Wells Fargo | Reiterated | Overweight | 2026-01-05 |
JMP Securities | Reiterated | Market Outperform | 2025-05-29 |
Cantor Fitzgerald | Reiterated | Overweight | 2025-04-28 |
Piper Sandler | Reiterated | Overweight | 2024-07-01 |
Truist Securities | Reiterated | Buy | 2023-09-20 |
Morgan Stanley | Reiterated | Equal Weight | 2023-03-30 |
BTIG | Downgraded | Buy → Neutral | 2023-02-02 |
Jefferies | Downgraded | Buy → Hold | 2023-02-01 |
Wedbush | Reiterated | Outperform | 2022-08-12 |
Guggenheim | Reiterated | Buy | 2021-12-16 |
One row per institution, most recent rating